Hims and Hers Health Inc (HIMS) Quote

Now it is climbing -- stupid stock it should have climbed up at the EU expansion news.

Selloff from $67s (?) to $51s over EU expansion seems nuts to me. This should have been good news for the stock price.
Obviously - what do I know?

I'm not seeing anything wrong with it. People are profit taking...this stock will do great, then one day, like Ozempic, they will discover you're gonna die sooner because of it, just with a smile on your face and they may not be able to close the lid on your coffin.

And I thought expansion into EU countries was a GOOD/POSITIVE news. Guess/definitely NOT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

You're right!!! My math is atrocious. More like $15 bucks ($13 is close enough).

Should I give you time to fix your post? It's down $18 from its all time high. It was at $67 a couple of days ago. It's now $53. Your math sucks.
It's forming a heck of a flag formation. You do understand charts, right?
I wish I had kept some of the shares I bought at $13.

Up $40 in 3 weeks and down $35 in 2 days and still going down. Hmmm?

It went from $25 to $65 in 3 weeks!!!!
What's your point?

Support level @ $52? From $67++ to $52s in 2 days. Hmmm?

It was the best of times; it was the WORST of times

HIMS one of the best performing mid caps last 52 weeks started core buys at 35.00 what a beast of stock. Riding free shares to the promise land.


$HIMS

Hims on a remarkable run! Looking for this to 2x by EOY and LFMD to 5x by end of year.

Patience grasshopper!

The other way

Squeeze time!

Earlier you said $13.50. Revisionist history?

Started buying this single digits riding free shares houses $.

Started buying this single digits riding free shares houses $.

Always early for big runners!

$HIMS

~I'm out .08c $516 calls 

Not for faint of heart! if one bought in Jan 10th or so in $24s to Feb 19th to $70s (6 week period): up almost 3X
then crashed back to $25s.
--> Not for the faint of heart

~bought some 5/16 $100 calls @.12c 

HIMS, 10Q due Monday 5/5

Beautiful comeback after the annihilation. I expect this to settle into the 50's.
The future growth still looks promising.

Hims & Hers Health Inc (HIMS.NaE) shares are tumbling Tuesday on the heels of the company’s fourth-quarter financial results. Here’s what you need to know.

What Happened: Hims & Hers Health (HIMS.NaE) reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to Benzinga Pro. The company reported fourth-quarter earnings of 11 cents per share, in line with analyst estimates.

Total revenue was up 69% on a year-over-year basis. Subscribers grew to 2.2 million in the quarter, up 45% year-over-year. Gross margin was 77% in the fourth quarter, which came up short of analyst estimates of 78.4%, according to CNBC.

Hims & Hers Health (HIMS.NaE) shares have been on a tear since the company said it would begin selling compounded versions of GLP-1 injections last year. The stock fell more than 20% on Friday after the U.S. Food and Drug Administration removed semaglutide injections from the shortage list. Hims & Hers said this week that its GLP-1 offering brought in over $225 million in revenue in 2024.

“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, co-founder and CEO of Hims & Hers Health (HIMS.NaE).

“In the coming years, we expect to further transform how individuals can improve their health with more comprehensive treatments, technologies that normalize unlimited follow up support, and tools that can eventually be exported beyond Hims and Hers, enabling even more Americans to access this care.”

See Also: DocuSign Boasts 13% Revenue Growth In Q4, Raises Full-Year Guidance Due To AI Momentum

Hims & Hers Health (HIMS.NaE) guided for first-quarter revenue of $520 million to $540 million. The company expects full-year 2025 revenue to be in the range of $2.3 billion to $2.4 billion versus estimates of $2.087 billion, according to Benzinga Pro.

Following the company’s quarterly results, Citigroup analyst Daniel Grosslight maintained Hims & Hers with a Sell and raised the price target from $25 to $27. Needham analyst Ryan MacDonald maintained a Buy rating and raised the price target from $31 to $61.

HIMS Price Action: Hims & Hers Health (HIMS.NaE) shares were down 19.6% at $41.15 at the time of publication Tuesday, according to Benzinga Pro.

Photo: Shutterstock.

Just slammed 20k in 36's myself. Love it.

This waaayyyyy overreacted to their reporting a weight loss drug. I just can't tell if the buyback is $35 or $29?

Buying the shares I sold at 57 back today 😁. I love these over reactions to good numbers and good guidance. Fundamentals have not changed here. Solid growth ahead for hims

Is this Jeopardy? OK, I'll play.....
What is the newest pump and dump?

HIMS, 10Q due MONDAY 2/24

NEWH

Mind boggling.

Great day!

$72 ouch for anyone short!

Weight loss made affordable nice play 

HIMS, new 52 week high

Truly incredible moves!

Shorts are getting wrecked! :)

$HIMS

HIMS holding a core at 13.50
Short % of Float (1/31/2025) 30.35%
Short % of Shares Outstanding (1/31/2025) 26.64%

$HIMS

OVER 41. Wow.

HIMS, new 52=high

Sharectile dysfunction? It can only stay up for so long.

hows is this 16% down premarket already today? what gives?

HIMS, just under the 52 week high

My luck was not paying attention to it too diligently...lol

I sold too soon, but to be fair, it already looks pricey.

Been one hell of a run. I took a few off. Been holding most from $6

Well, it sure hit $32 quickly enough. Now do we see the big breakout, or pullback? I should have taken my own advice here...

If you had played this stock right, it would have made for a nice roller coaster. I rode it once from $13 to $19. It looks like the next stop may be around $32.
Of course it is also the epitome of a high risk stock.

HIMS, new 52 week high

I wish for a world in which they are able to punish these laughable selloffs on some lukewarm excuse...
As seen in ADMA, HOOD, TSLA and here. Technically its fine... Practically what they are doing is an orchestrated maneuver to scam gullible investors living on buy/sell panic diet

HIMS new 52 week high

HIMS 10Q 11/4